Jordana Joy

5 days ago | optometrytimes.com | Jordana Joy

Takeaways from this week in optometry: May 5 - May 9Catch up on the top stories in optometry during the week of May 5-May 9. Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

6 days ago | ophthalmologytimes.com | Jordana Joy

Biopharmaceutical company Perfuse Therapeutics has announced positive 24-weeks results from its Phase 1/2a trial of PER-001, a first-in-class endothelin antagonist intravitreal implant for glaucoma.1 Data from the completed trial was presented at the Association for Research in Vision and Ophthalmology (ARVO) meeting earlier this week, according to a news release.

6 days ago | optometrytimes.com | Jordana Joy

Biopharmaceutical company Perfuse Therapeutics has announced positive 24-weeks results from its Phase 1/2a trial of PER-001, a first-in-class endothelin antagonist intravitreal implant for glaucoma.1 Data from the completed trial was presented at the Association for Research in Vision and Ophthalmology (ARVO) meeting earlier this week, according to a news release.

6 days ago | optometrytimes.com | Jordana Joy

Prevent Blindness has vocalized its full support of the recent reintroduced of the Early Detection of Vision Impairments for Children Act (EDVI), or HR 2527, in the US House of Representatives.1 The bipartisan legislation would work to establish grants for states and communities to apply for and access for the implementation of new approaches and improved public education regarding children’s vision, early detection of vision concerns, referrals for eye examinations, and follow-up mechanisms,...

1 week ago | ophthalmologytimes.com | Jordana Joy

Biopharmaceutical company Innovent Biologics has completed the first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa for the treatment of diabetic macular edema (DME).1 The recombinant human vascular endothelial growth factor receptor (VEGFR)-antibody human complement receptor 1 (CR1) fusion protein was intravitreally administered in DME patients in the randomized, double-masked, multi-center, active-controlled trial (NCT06908876), which assessed the therapy’s efficacy...